SG Americas Securities LLC Sells 31,133 Shares of Edwards Lifesciences Co. (NYSE:EW)

SG Americas Securities LLC decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 80.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,429 shares of the medical research company’s stock after selling 31,133 shares during the period. SG Americas Securities LLC’s holdings in Edwards Lifesciences were worth $875,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. LPL Financial LLC increased its holdings in Edwards Lifesciences by 8.3% during the fourth quarter. LPL Financial LLC now owns 285,359 shares of the medical research company’s stock valued at $36,968,000 after buying an additional 21,931 shares during the last quarter. Krilogy Financial LLC purchased a new stake in shares of Edwards Lifesciences in the first quarter worth $806,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth $1,067,000. Bartlett & Co. LLC increased its stake in shares of Edwards Lifesciences by 3.7% in the fourth quarter. Bartlett & Co. LLC now owns 6,783 shares of the medical research company’s stock worth $879,000 after purchasing an additional 240 shares in the last quarter. Finally, Aberdeen Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth $228,000. Institutional investors own 82.54% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $100.54 on Monday. The firm has a 50-day moving average price of $96.78 and a 200-day moving average price of $105.68. The firm has a market capitalization of $62.51 billion, a PE ratio of 41.21, a price-to-earnings-growth ratio of 2.95 and a beta of 1.14. The company has a current ratio of 3.41, a quick ratio of 2.64 and a debt-to-equity ratio of 0.10. Edwards Lifesciences Co. has a 12-month low of $85.58 and a 12-month high of $131.73.

Edwards Lifesciences (NYSE:EW – Get Rating) last released its earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by ($0.01). The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 25.80% and a net margin of 28.72%. Edwards Lifesciences’s revenue was down .2% compared to the same quarter last year. During the same quarter last year, the business posted $0.64 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on EW shares. Morgan Stanley reduced their price objective on shares of Edwards Lifesciences from $136.00 to $119.00 and set an “overweight” rating for the company in a research note on Friday, July 15th. William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences in a research note on Tuesday, April 26th. Cowen cut their target price on shares of Edwards Lifesciences from $140.00 to $125.00 in a research note on Monday, July 11th. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Finally, Stifel Nicolaus cut their target price on shares of Edwards Lifesciences from $128.00 to $115.00 in a research note on Monday, July 18th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $126.55.

Insider Buying and Selling

In related news, CEO Michael A. Mussallem sold 19,875 shares of the firm’s stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $95.88, for a total value of $1,905,615.00. Following the transaction, the chief executive officer now owns 166,853 shares of the company’s stock, valued at approximately $15,997,865.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, VP Donald E. Bobo, Jr. sold 6,725 shares of the firm’s stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $90.02, for a total value of $605,384.50. Following the transaction, the vice president now owns 62,561 shares of the company’s stock, valued at approximately $5,631,741.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael A. Mussallem sold 19,875 shares of the firm’s stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $95.88, for a total transaction of $1,905,615.00. Following the transaction, the chief executive officer now directly owns 166,853 shares in the company, valued at approximately $15,997,865.64. The disclosure for this sale can be found here. Insiders have sold 138,443 shares of company stock valued at $13,291,621 in the last 90 days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Read More

• Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
• Use These To Find Your Stock’s Support and Resistance Levels
• Is Boeing Stock is Ready for Lift-Off ?
• Elon Musk is Out, But Should You Be In Twitter Stock?
• 3 Earnings Announcements That Could Surprise
• Twitter’s Up For Third Week In A Row: What’s Next For The Stock?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Get Rating).

Want More Great Investing Ideas?